UK’s MHRA revokes authorisation for Novartis’ sickle cell drug, ET HealthWorld

[ad_1]

Bengaluru: Britain’s health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis’ sickle cell disease drug, Adakveo.

The decision follows the Swiss drugmaker’s move to recall a batch of the drug after the Medicines and Healthcare products Regulatory Agency (MHRA) said it no longer considered the treatment’s benefits-to-risk balance favourable.

Sickle cell disease is a genetic disorder in which misshapen blood cells cause strokes, organ damage, severe pain and early death.

The European Medicines Agency (EMA) also revoked approval for the drug last year.

  • Published On Feb 21, 2024 at 06:22 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *